WHY IT MATTERS: Patients managing anxiety who are curious about cannabis now have additional research supporting CBD-dominant products as a potentially effective option worth discussing with a knowledgeable clinician before making any changes to current treatment. CLINICAL OVERVIEW: CBD-dominant cannabis products are gaining clinical attention as a potential option for anxiety management, with research suggesting meaningful symptom relief in patients who use formulations where cannabidiol predominates over THC. The anxiolytic properties of CBD are thought to involve serotonergic signaling and modulation of the endocannabinoid system, particularly at CB1 receptors and 5-HT1A receptors, which distinguishes its mechanism from both benzodiazepines and SSRIs.
First Human Clinical Trial: CBG Reduces Anxiety and Stress Without Intoxication
If Texas—one of America’s most conservative states and a major hemp producer—signals voter support for legalization, it could dramatically accelerate federal cannabis reform that affects your access to products. In one of the first double-blind, placebo-controlled clinical trials of isolated CBG in humans, a 20mg oral dose of hemp-derived cannabigerol produced statistically significant reductions in subjective anxiety and stress, along with improved verbal memory, without intoxication, cognitive slowing, or motor impairment. The study of 34 healthy adults suggests CBG may influence stress and anxiety pathways without producing typical ‘drug effects.’ Researchers emphasize preliminary nature and need for replication.